RxDoctor Payments Data

Gary Marshall

Pediatric Infectious Diseases · Louisville, KYNPI 1720062268

Payments from drug & device makers

$1,869,025in general payments, 2019–2025

Across 351 payments — averaging $5324.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$1.3M
  • Sanofi Pasteur Inc.$233K
  • GSK$97K
  • Merck$75K
  • Modernatx, Inc.$48K
  • Seqirus USA Inc$41K
  • plus $42K from 2 others
$10,339in research payments, 2019–2025

Across 20 payments — averaging $516.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$8K
  • GSK$2K

What the payments were for

  • Consulting fees$230,07758%
  • Speaking & faculty fees$114,95529%
  • Grants$8000%
  • Travel & lodging$42,22311%
  • Food & beverage$7,3482%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer(2 entities)118$1,333,894
Sanofi Pasteur Inc.66$232,844
GSK43$96,794
Merck66$75,033
Modernatx, Inc.18$47,527
Seqirus USA Inc19$41,222
AstraZeneca20$39,430
Sobi, Inc1$2,280

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few pediatric infectious diseases providers in Kentuckyto place this figure against a meaningful peer group, so we don't.

Other pediatric infectious diseases in Louisville

Where these figures come from

Is this you, or does something look wrong? →